Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

"http://www.avidbio.com" target="_new">http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Md., May 5, 2011 GenVec, Inc. (NASDAQ: GNVCD) today ... letter from The NASDAQ Stock Market ("NASDAQ") advising that it ... GenVec had received a notice of deficiency on ... compliance with NASDAQ Marketplace Rules because the bid price of ...
... Reportlinker.com announces that a new market research report ... Tumor Markers - Global Pipeline Analysis, Competitive Landscape ... http://www.reportlinker.com/p0490349/Tumor-Markers---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html Tumor Markers - ... to 2017 Summary ...
... 4, 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... material, today announced that its chairman and CEO, Guy Cook, ... Equity Conference at the Hard Rock Hotel in Hollywood, Florida, ... At the time of the presentation, a live audio ...
Cached Biology Technology:GenVec Regains Compliance with NASDAQ Listing Requirements 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:7/10/2014)... are a big, bad sea scorpion. , One minute, ... any prey in sight. The next, thanks to a ... to trolling for weaker, soft-bodied animals you stumble upon ... giant pterygotid eurypterid, the largest arthropod that ever lived. ... journal Biology Letters , dramatically re-interprets the creature,s ...
(Date:7/10/2014)... The controversy centres around a family of enzymes known ... heme group in their active site. At the centre ... which becomes oxidised (ferryl) when a reacting heme is ... that has remained unanswered for decades is whether this ... hydroxyl group (OH). Resolving this fundamental question has implications ...
(Date:7/10/2014)... research from The University of Texas Health Science Center ... Real (IYG), a health education program designed to delay ... reduce dating violence behaviors among minority youth. , According ... percent of high school youth are victims of physical ... 20 percent are victims of emotional dating violence. Previous ...
Breaking Biology News(10 mins):Extinct sea scorpion gets a Yale eye exam, with surprising results 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... Brian Chen has been awarded a prestigious Sloan Research ... Formation, investigates a big subject: deciphering the assembly instructions ... neural circuits wire up with precision. One of the ... the correct synaptic contacts during its development when faced ...
... named Brontomerus mcintoshi , or "thunder-thighs" after its enormously powerful ... is described in a paper recently published in the journal ... the U.K. and the U.S. A member of the ... Brachiosaurus , Brontomerus may have used its powerful ...
... the crowd? Is that all I,ll ever be? ... Do you ... the Crowd" It may seem paradoxical, but being ... UCLA life scientists. Biologists Kimberly Pollard and Daniel ... alarm-call vocalizations in eight species of rodents that live in social ...
Cached Biology News:Prestigious Sloan Fellowship awarded 2New 'thunder-thighs' dinosaur discovered 2New 'thunder-thighs' dinosaur discovered 3Even in a crowd, you remain unique, UCLA life scientists report 2
...
...
... The T7 Phage Capture Plate is a 96-well ... which the T7 Tail Fiber Monoclonal Antibody is ... activity. The antibody specifically recognizes the tail fiber ... plate has a capacity of 10 9 ...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
Biology Products: